Ibrutinib-Rituximab Beats Chemoimmunotherapy for CLL
Progression-free, overall survival improved in the ibrutinib-rituximab group at three years
Childhood BMI, HDL-C Variability May Up Later-Life Diabetes Risk
Greater variability tied to higher risk, independent of mean levels for BMI, HDL cholesterol in childhood
